Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ANGLE plc ( (GB:AGL) ) has issued an update.
ANGLE plc reported interim results for the first half of 2025, highlighting successful completion of contracts with major pharma companies like Eisai and AstraZeneca, despite facing revenue pressures due to adverse market conditions. The company has developed a unique DNA dual analysis assay using Illumina NGS, expanding its market reach and enhancing its product offerings. ANGLE continues to face challenges from external conditions such as US policy volatility and tariff uncertainties, which have delayed new projects and collaborations. However, the company remains optimistic about its growth potential with ongoing discussions for new contracts and collaborations, including a significant partnership with Myriad Genetics to adapt a cancer test to a CTC-based sample using ANGLE’s Parsortix system.
The most recent analyst rating on (GB:AGL) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
Spark’s Take on GB:AGL Stock
According to Spark, TipRanks’ AI Analyst, GB:AGL is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flows. Technical analysis shows some positive momentum, but valuation concerns due to negative earnings weigh heavily on the score.
To see Spark’s full report on GB:AGL stock, click here.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, specializing in innovative circulating tumor cell (CTC) solutions used in research, drug development, and clinical oncology. The company focuses on providing advanced diagnostic tools and services to large pharmaceutical and medtech companies, enhancing cancer diagnostics and treatment.
Average Trading Volume: 748,593
Technical Sentiment Signal: Sell
Current Market Cap: £21.77M
Find detailed analytics on AGL stock on TipRanks’ Stock Analysis page.